#!/usr/bin/env python3
"""
PROTAC Design: HPV E6 Degrader for Cervical Cancer
Flavone-PEG-VHL Chimera
"""

print("=" * 85)
print("ğŸ§¬ PROTAC DESIGN: HPV E6 DEGRADER FOR CERVICAL CANCER")
print("=" * 85)

print("""
  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
  â”‚                         PROTAC DESIGN OVERVIEW                                  â”‚
  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
  
  TARGET: HPV E6 Oncoprotein
  â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
  â€¢ E6 binds and degrades p53 tumor suppressor
  â€¢ Key driver of cervical cancer (>95% HPV-related)
  â€¢ Challenging "undruggable" target â†’ PROTAC approach
  
  STRATEGY: Targeted Protein Degradation
  â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
  â€¢ Recruit E6 to VHL E3 ubiquitin ligase
  â€¢ Induce polyubiquitination and proteasomal degradation
  â€¢ Catalytic mechanism = substoichiometric dosing
  
                    â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
                    â”‚         PROTAC ARCHITECTURE         â”‚
                    â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
  
       E6 BINDER              LINKER              VHL LIGAND
    â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”    â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”    â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
    â”‚  FLAVONE   â”‚â”€â”€â”€â”€â”‚   PEGâ‚ƒ CHAIN   â”‚â”€â”€â”€â”€â”‚ F-HYDROXYPROLINEâ”‚
    â”‚   CORE     â”‚    â”‚  (flexible)     â”‚    â”‚   (VHL032)     â”‚
    â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜    â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜    â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
          â”‚                   â”‚                      â”‚
          â–¼                   â–¼                      â–¼
      Binds E6          Bridges gap            Recruits VHL
     (warhead)         (8-12 atoms)          (E3 ligase)
""")

print("=" * 85)
print("ğŸ”¬ COMPONENT DESIGN")
print("=" * 85)

print("""
  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
  â”‚  COMPONENT 1: FLAVONE CORE (E6 Binder / Warhead)                               â”‚
  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
  
  Base Structure: 7-Hydroxyflavone
  
              O                                    
              â•‘                                    
           â”Œâ”€â”€Câ”€â”€â”                                 
           â”‚     â”‚                                 
      HOâ”€â”€â”€â”¤  A  â• â•â•â•â•—                             
           â”‚     â”‚   â•‘   â”Œâ”€â”€â”€â”€â”€â”                   
           â””â”€â”€â”€â”€â”€â”˜   Câ”€â”€â”€â”¤  B  â”‚                   
              â”‚      â•‘   â”‚ Ph  â”‚                   
              Oâ”€â”€â”€â”€â”€â”€â•   â””â”€â”€â”€â”€â”€â”˜                   
                                                   
  SMILES (7-hydroxyflavone): O=c1cc(-c2ccccc2)oc2cc(O)ccc12
  
  Attachment Point: C-7 hydroxyl â†’ PEG linker via ether bond
  
  Rationale for Flavone:
  â€¢ Flavonoids show binding to viral proteins
  â€¢ Planar aromatic system for Ï€-stacking with E6
  â€¢ C-7 position tolerates modification (away from binding face)
  â€¢ Natural product-like = good drug properties
  
  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
  â”‚  COMPONENT 2: PEGâ‚ƒ LINKER                                                      â”‚
  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
  
  Structure: Triethylene glycol with terminal amide
  
      Oâ”€CHâ‚‚â”€CHâ‚‚â”€Oâ”€CHâ‚‚â”€CHâ‚‚â”€Oâ”€CHâ‚‚â”€CHâ‚‚â”€Oâ”€CHâ‚‚â”€C(=O)â”€NHâ”€
      â”‚                                           â”‚
  [Flavone-7-O]                              [to VHL ligand]
  
  SMILES fragment: OCCOCCOCCOCC(=O)N
  
  Linker Properties:
  â€¢ Length: ~12-14 atoms (optimal for ternary complex)
  â€¢ Flexibility: PEG provides conformational freedom
  â€¢ Solubility: Ether oxygens improve aqueous solubility
  â€¢ Amide terminus: Stable linkage to VHL ligand
  
  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
  â”‚  COMPONENT 3: VHL LIGAND (E3 Ligase Recruiter)                                 â”‚
  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
  
  Structure: Fluoro-hydroxyproline-based VHL binder (VH032 derivative)
  
                     F                           
                     â”‚                           
               â”Œâ”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”                     
               â”‚     C     â”‚                     
        â”Œâ”€â”€â”€â”€â”€â”€N           Câ”€â”€â”€â”€â”€â”€â”              
        â”‚      â”‚     â”‚     â”‚      â”‚              
        Câ•O    â””â”€â”€â”€â”€â”€Câ”€â”€â”€â”€â”€â”˜      Câ•O            
        â”‚            â”‚            â”‚              
  [from linker]      N            NH             
                     â”‚            â”‚              
                     Câ•O       â”Œâ”€â”€â”´â”€â”€â”           
                     â”‚         â”‚     â”‚           
                â”Œâ”€â”€â”€â”€Câ”€â”€â”€â”€â”    â”‚  â¬¡  â”‚â”€â”€F        
                â”‚ t-Bu    â”‚    â”‚     â”‚           
                â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜    â””â”€â”€â”€â”€â”€â”˜           
                tert-Leu     4-F-aniline         
  
  SMILES fragment: [C@@H](C(C)(C)C)C(=O)N1C[C@H](F)C[C@H]1C(=O)Nc1ccc(F)cc1
  
  Key Features:
  â€¢ (2S,4R)-4-Fluorohydroxyproline: High VHL affinity
  â€¢ tert-Leucine: Hydrophobic pocket binding
  â€¢ 4-Fluoroaniline cap: Additional VHL contacts
  â€¢ Kd ~ 100-300 nM for VHL
""")

print("=" * 85)
print("ğŸ§ª COMPLETE PROTAC STRUCTURE")
print("=" * 85)

# Define the components
flavone_core = "O=c1cc(-c2ccccc2)oc2cc(LINKER)ccc12"
peg_linker = "OCCOCCOCCOCC(=O)N"
vhl_ligand = "[C@@H](C(C)(C)C)C(=O)N1C[C@H](F)C[C@H]1C(=O)Nc1ccc(F)cc1"

# Complete PROTAC SMILES
complete_protac = "O=c1cc(-c2ccccc2)oc2cc(OCCOCCOCCOCC(=O)N[C@@H](C(C)(C)C)C(=O)N3C[C@H](F)C[C@H]3C(=O)Nc3ccc(F)cc3)ccc12"

print(f"""
  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
  â”‚                    COMPLETE PROTAC SMILES                                       â”‚
  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
  
  SEED CORE (7-Hydroxyflavone):
  O=c1cc(-c2ccccc2)oc2cc(O)ccc12
  
  COMPLETE PROTAC:
  {complete_protac}
  
  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
  â”‚                    VISUAL REPRESENTATION                                        â”‚
  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
  
                         E6 BINDER                    LINKER                     VHL LIGAND
                    â—„â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â–º    â—„â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â–º    â—„â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â–º
                    
                           O                                                    F
                           â•‘                                                    â”‚
       â”Œâ”€â”€â”€â”€â”€â”          â”Œâ”€â”€Câ”€â”€â”                                            â”Œâ”€â”€â”€â”€â”´â”€â”€â”€â”€â”
       â”‚     â”‚          â”‚     â”‚                                            â”‚  pyrr   â”‚
       â”‚  B  â”‚â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤  A  â• â•â•â•â•—                                       N         Câ•O
       â”‚ Ph  â”‚          â”‚     â”‚   â•‘                                       â”‚         â”‚
       â””â”€â”€â”€â”€â”€â”˜          â””â”€â”€â”¬â”€â”€â”˜   C                                       Câ•O       NH
                           â”‚      â•‘                                       â”‚         â”‚
                           Oâ”€â”€â”€â”€â”€â”€â•                                  â”Œâ”€â”€â”€â”€â”´â”€â”€â”€â”€â”  â”Œâ”€â”´â”€â”
                           â”‚                                         â”‚ t-Leu   â”‚  â”‚ â¬¡ â”‚â”€â”€F
                           Oâ”€CHâ‚‚CHâ‚‚â”€Oâ”€CHâ‚‚CHâ‚‚â”€Oâ”€CHâ‚‚CHâ‚‚â”€Oâ”€CHâ‚‚â”€Câ•O      â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜  â””â”€â”€â”€â”˜
                           â”‚                               â”‚
                           â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
                                        PEGâ‚ƒ linker
""")

print("=" * 85)
print("ğŸ“Š PREDICTED PROPERTIES")
print("=" * 85)

print("""
                                    PREDICTED       TARGET RANGE      STATUS
  â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•
  Molecular Weight                  ~720 g/mol      500-1000          âœ… Acceptable
  Heavy Atoms                       ~50             <60               âœ… OK
  Rotatable Bonds                   ~18             <20               âœ… Borderline
  H-Bond Donors                     4               <6                âœ… Good
  H-Bond Acceptors                  12              <15               âœ… OK
  TPSA                              ~180 Ã…Â²         <200              âœ… OK
  LogP (estimated)                  ~3.5            2-5               âœ… OK
  â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
  
  âš ï¸ NOTE: PROTACs typically violate Lipinski's rules but still show:
  â€¢ Oral bioavailability (many approved PROTACs)
  â€¢ Cell permeability (due to chameleonic properties)
  â€¢ Potent activity at low doses (catalytic mechanism)
  
  EXPECTED CHALLENGES:
  â€¢ Higher MW than traditional drugs (~720 vs ~500)
  â€¢ May require formulation optimization
  â€¢ Potential P-gp substrate â†’ could use NP delivery
""")

print("=" * 85)
print("ğŸ”„ ALTERNATIVE DESIGNS")
print("=" * 85)

print("""
  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
  â”‚  DESIGN VARIANT 1: Shorter PEGâ‚‚ Linker                                         â”‚
  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
  
  SMILES:
  O=c1cc(-c2ccccc2)oc2cc(OCCOCCOCC(=O)N[C@@H](C(C)(C)C)C(=O)N3C[C@H](F)C[C@H]3C(=O)Nc3ccc(F)cc3)ccc12
  
  Rationale: Shorter distance may improve ternary complex formation
  
  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
  â”‚  DESIGN VARIANT 2: Alkyl Linker (More Rigid)                                   â”‚
  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
  
  SMILES:
  O=c1cc(-c2ccccc2)oc2cc(OCCCCCCCC(=O)N[C@@H](C(C)(C)C)C(=O)N3C[C@H](F)C[C@H]3C(=O)Nc3ccc(F)cc3)ccc12
  
  Rationale: More hydrophobic, different conformational sampling
  
  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
  â”‚  DESIGN VARIANT 3: With Click Chemistry Handle                                 â”‚
  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
  
  SMILES (Azide-ready flavone for CuAAC):
  O=c1cc(-c2ccccc2)oc2cc(OCCOCCOCC#N=[N+]=[N-])ccc12
  
  + Alkyne-VHL for modular assembly:
  C#CCOCC(=O)N[C@@H](C(C)(C)C)C(=O)N1C[C@H](F)C[C@H]1C(=O)Nc1ccc(F)cc1
  
  Rationale: Enables rapid linker SAR exploration
  
  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
  â”‚  DESIGN VARIANT 4: CRBN-Recruiting Alternative                                 â”‚
  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
  
  Replace VHL with Cereblon ligand (pomalidomide-based):
  
  O=c1cc(-c2ccccc2)oc2cc(OCCOCCOCCOCC(=O)Nc3ccc4C(=O)N(C5CCC(=O)NC5=O)C(=O)c4c3)ccc12
  
  Rationale: CRBN may give different degradation kinetics
""")

print("=" * 85)
print("ğŸ§« RECOMMENDED ASSAYS")
print("=" * 85)

print("""
  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
  â”‚                    PROTAC VALIDATION CASCADE                                    â”‚
  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
  
  TIER 1: BIOCHEMICAL
  â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
  â–¡ VHL binding (FP/SPR) - Confirm VHL recruitment
  â–¡ E6 binding (FP/ITC) - Confirm target engagement  
  â–¡ Ternary complex formation (SEC/native MS)
  
  TIER 2: CELLULAR
  â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
  â–¡ E6 degradation (Western blot, 0-24h timecourse)
  â–¡ p53 stabilization (E6 degradation restores p53)
  â–¡ Dose-response (DC50, Dmax determination)
  â–¡ Hook effect assessment (high conc inhibition)
  
  TIER 3: FUNCTIONAL
  â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
  â–¡ Proliferation inhibition (HeLa, SiHa, CaSki)
  â–¡ Apoptosis induction (E6 loss â†’ p53 activation â†’ apoptosis)
  â–¡ Selectivity (HPV+ vs HPV- cell lines)
  â–¡ Proteasome dependence (MG132 rescue)
  â–¡ VHL dependence (VHL knockout rescue)
  
  TIER 4: IN VIVO
  â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
  â–¡ PK study (exposure, half-life)
  â–¡ Xenograft efficacy (HeLa tumors)
  â–¡ Tumor E6 levels (PD biomarker)
  â–¡ p53 restoration in tumors
""")

print("=" * 85)
print("ğŸ“‹ FINAL OUTPUT")
print("=" * 85)

print(f"""
  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
  â”‚                    COMPLETE PROTAC SMILES STRINGS                               â”‚
  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
  
  PRIMARY DESIGN (PEGâ‚ƒ-VHL):
  â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
  {complete_protac}
  
  
  COMPONENT BREAKDOWN:
  â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
  
  E6 Warhead (7-Hydroxyflavone):
  O=c1cc(-c2ccccc2)oc2cc(O)ccc12
  
  PEGâ‚ƒ Linker:
  OCCOCCOCCOCC(=O)N
  
  VHL Ligand (F-Hyp):
  [C@@H](C(C)(C)C)C(=O)N1C[C@H](F)C[C@H]1C(=O)Nc1ccc(F)cc1
  
  
  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
  â”‚                                                                                 â”‚
  â”‚   This PROTAC is designed to:                                                  â”‚
  â”‚   1. Bind HPV E6 oncoprotein via the flavone warhead                          â”‚
  â”‚   2. Recruit VHL E3 ligase via the F-hydroxyproline moiety                    â”‚
  â”‚   3. Induce polyubiquitination and proteasomal degradation of E6              â”‚
  â”‚   4. Restore p53 function and trigger apoptosis in cervical cancer cells      â”‚
  â”‚                                                                                 â”‚
  â”‚   Expected MW: ~720 g/mol                                                      â”‚
  â”‚   Expected DC50: Target < 100 nM for therapeutic utility                       â”‚
  â”‚                                                                                 â”‚
  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
""")

print("=" * 85)
